Quick Facts
FONT-SIZE Plus   Neg
Share SHARE
mail  E-MAIL

Ipsen's Partner Announces Hold Of Phase III Trials Of IB1001 For Hemophilia B

7/10/2012 1:14 AM ET

Ipsen's (IPSEF.PK) partner, Inspiration Biopharmaceuticals Inc., was notified by the Food and Drug Administration or FDA that both studies evaluating the safety and efficacy of IB1001, an investigational intravenous recombinant factor IX (rFIX) therapy for the treatment and prevention of bleeding episodes in people with hemophilia B, were placed on clinical hold.

The clinical hold impacts 2 ongoing IB1001 clinical trials such as a phase III study evaluating the safety and efficacy of IB1001 to treat and prevent bleeding episodes in adults with hemophilia B, and a phase III study evaluating IB1001 to treat and prevent bleeding episodes in previously treated pediatric subjects with hemophilia B.

The adult study has completed its primary analysis period. Following the FDA's request, Inspiration has notified clinical sites in the U.S. to hold treatment of patients with IB1001. Also, Inspiration Biopharmaceuticals is sharing the FDA directive with regulators in countries outside of the U.S. where the studies are being conducted.

Totally, 86 people with hemophilia B have received IB1001 in trials and, to date, no adverse events related to the development of antibodies to CHO protein have been reported. Moreover, no relationship has been showed between the development of antibodies to CHO protein and the development of any antibodies to factor IX, the company added.

Register
To receive FREE breaking news email alerts for Ipsen Promesses and others in your portfolio

by RTT Staff Writer

For comments and feedback: editorial@rttnews.com

Business News

Quick Facts

Editors Pick
While Republicans will try to use the troubled rollout of Obamacare to their advantage in the upcoming midterm elections, the results of a Reuters/Ipsos poll showed that Americans increasingly think Democrats have a better plan for healthcare. Nearly three hundred people are still unaccounted for after a ferry carrying 462 people capsized and sank off South Korea's southern coast, media reports citing local officials said Wednesday. The ill-fated ferry, carrying mostly high school students on an overnight trip, was heading to the tourist island of Jeju from the city of Incheon, a northwestern South Korean city that houses the country's After moving mostly higher in early trading on Wednesday, stocks have continued to perform well over the course of the session. While buying interest has waned since then open, the markets have maintained a positive bias on the day.
comments powered by Disqus
FREE Newsletters, Analysis & Alerts

 

Stay informed with our FREE daily Newsletters and real-time breaking News Alerts. Sign up to receive the latest information on business news, health, technology, biotech, market analysis, currency trading and more.